Healthcare Middle Market Financing: Navigating Complexity in Private Equity’s Most Active Sector

Healthcare private equity delivered a record performance in 2025, with disclosed deal value exceeding an estimated $191 billion — surpassing the previous high set in 2021. Deal activity was similarly robust, with investors announcing an estimated 445 buyouts, marking the second-highest annual total on record.¹ Exit value rebounded to $156 billion from $54 billion in 2024 as sponsor-to-sponsor deals returned, with more than 30 such transactions exceeding $1 billion compared to just eight the prior year.²

Yet financing healthcare companies — particularly in the middle market — presents complexity that few general lenders fully appreciate. The sector’s unique characteristics, from reimbursement timing to regulatory scrutiny, create both risk and opportunity for specialty lenders who invest in the capabilities required to underwrite these credits effectively. As one industry veteran notes, “detailed investigation of industry nuances and trends will reveal that asset-based lending to the healthcare industry is not an area to dabble in and definitely not for the faint of heart.”³

Record Activity Driven by Provider IT and Technology-Enabled Assets

Provider IT and services drove 2025’s growth, with healthcare IT deal value within the provider segment doubling to an estimated $32 billion.⁴ This was led by Warburg Pincus’s sale of its majority interest in ModMed, a provider IT company, to Clearlake Capital at a valuation exceeding $5 billion. According to Bain & Company analysis, investors sharpened focus on technology-enabled assets including analytics, workforce optimization and platform solutions.

PE firms are increasingly investing in assets that improve operational efficiencies for providers, targeting technology that optimizes revenue cycle management, software that enhances workforce management, and AI automation technology.⁵ A Deloitte survey of 80 top executives from U.S. health systems and health plans found that one-third identified technology investments as a priority for 2025. The fragmented nature of healthcare technology presents opportunities for PE firms to consolidate and create value through economies of scale.

Mid-market healthcare-focused funds — ranging between $500 million and $4 billion in assets under management — have historically outperformed the broader market, benefiting from continued innovation and evolution of their investment strategies.⁶ These funds have maintained buyout deal activity and exits since 2020 even as the broader healthcare buyout market struggled. Fund-raising reflects this performance: mid-market funds with healthcare exposure have raised approximately $59 billion since 2022, exceeding fund-raising in the previous three years by about 40%.

Sector-Specific Opportunities: Infusion, Home Health, and Beyond PPM

Several tailwinds continue to fuel opportunities in infusion services in 2025. The market remains highly fragmented, faces relatively light regulation, and creates business synergies with physician practice management platforms.⁷ PE interest is driven primarily by increasing specialized IV-based drug products and treatment programs, with low-to-medium acuity services generally provided at lower rates outside inpatient settings. The first quarter saw both the announcement and completion of Optum’s acquisition of FlexCare Infusion from RC Capital.

Home-based healthcare leads all sectors for healthcare services deals according to PitchBook data, with the highest number of acquisition deals in the first quarter of 2025.⁸ Investment by national players demonstrates ongoing PE interest, including Pennant Group’s acquisition of Signature Healthcare at Home’s Oregon assets and the acquisition of BrightStar Care by Peak Rock Capital. COVID-19 accelerated the trend toward in-home care, and its popularity with patients and ability to reduce costs are well established.

Physician practice management platforms have fallen somewhat out of favor with certain PE investors over the last 18-24 months due to regulatory pressure, though they remain a core portfolio asset in the U.S. middle market.⁹ According to Bain analysis, investors are “retooling their physician group approach, building performance-driven platforms for the long term and positioning assets for strategic exits.” The value-creation playbook has expanded beyond traditional buy-and-build strategies toward operational excellence including improvements in access, workflow, and care coordination enabled by data, analytics, and AI.

Healthcare ABL: Navigating Collateral Complexity

Asset-based lending to healthcare companies requires specialized infrastructure that reflects the sector’s unique receivables characteristics. According to SLR Healthcare ABL, typical partner clients have annual revenue of $20 million or more with financing needs of $2-40 million, financing receivables due from Medicare, Medicaid, commercial insurers, corporate payors and other healthcare providers.¹⁰ These relationships typically consist of revolving lines of credit, sometimes supplemented by senior term loans or real estate loans tailored to unique circumstances.

The complexity of healthcare receivables valuation cannot be overstated. The difference between gross amounts billed and amounts expected to be collected ranges widely from sector to sector and company to company. Factors affecting ultimate collection include provider type, ultimate payor, billing practices, systems and even geographic location. It is not uncommon for one provider to have low single-digit contractual and non-contractual dilution while another in the same sector has 20-30% dilution.¹¹ Some sectors commonly exhibit net payment rates in the high teens — effectively 80% dilution.

Healthcare receivables face unique risks including potential offset rights from government payors, documentation requirements that become increasingly complex with constantly changing rules, and compliance requirements subject to ambiguous interpretation. Non-compliance outcomes range from managerial distraction to extended litigation, settlements and business failure — and these claims can prime lender collateral or directly offset otherwise valid receivables.¹²

According to CAIA analysis, modern ABL has evolved its collateral set to include healthcare-specific assets: healthcare, drug royalties and life sciences receivables.¹³ This expansion has enabled private lenders to structure loans aligned with the unique characteristics of specific healthcare sub-sectors, making ABL applicable to segments previously underrepresented in traditional private credit allocations. The self-amortizing nature of many ABL structures — where loans are repaid directly from cash flows of underlying assets — provides risk mitigation advantages particularly valuable in healthcare’s reimbursement environment.

Regulatory Headwinds and Distress Dynamics

A convergence of macroeconomic and regulatory headwinds weighed heavily on healthcare M&A in 2025. Elevated borrowing costs and tight credit markets dampened leverage-driven returns, while more exacting diligence requirements extended timelines and increased execution risk.¹⁴ The lower middle market experienced sustained pressure, with add-on acquisitions proving increasingly difficult to execute amid heightened regulatory, financing and operational constraints.

State-level regulatory activity intensified. In October 2025, California Governor Gavin Newsom signed Senate Bill 351 and Assembly Bill 1415 into law to curb investor influence in healthcare.¹⁵ These laws represent the latest in a flurry of state legislative activity bringing greater oversight and transparency to healthcare M&A, regulating certain PE business strategies, and updating corporate practice of medicine law. Massachusetts enacted similar legislation in January 2025 strengthening oversight of private equity firms and other major market groups.

In the third quarter of 2025, 12 healthcare companies commenced Chapter 11 cases, with four involving liabilities exceeding $500 million. These mega filings, including Genesis Healthcare and Prospect Medical Holdings, demonstrate that even large-scale, PE-backed healthcare organizations are not immune from financial pressures.¹⁶ An increasing number of healthcare companies have addressed distress through liability management exercises, negotiating with key stakeholders to deleverage balance sheets and obtain new funding with extended maturities.

Ecosystem Implications

For Private Credit Lenders and Specialty Finance Providers: Healthcare ABL requires dedicated teams managing broad healthcare portfolios, concentrating industry knowledge and experience to serve borrowers while managing credit risk effectively. The best-positioned lenders are involved across multiple sub-sectors, living and breathing the business daily where risk and opportunity are identified as developments in one sector predict impact on another. According to Secured Research analysis, healthcare specialty lenders command yield premiums of 150-250 basis points over generalist ABL providers, reflecting both complexity and the scarcity of genuine sector expertise.

For PE Sponsors: Mounting exit pressure — with many sponsors holding healthcare assets beyond traditional investment horizons — makes realizations a strategic imperative amid new fundraising cycles.¹⁷Successful exits increasingly require operational sophistication: platforms showing sustainable growth and employer-of-choice positioning for clinicians are better positioned for sponsor-to-sponsor sales or strategic exits. The shift from pure buy-and-build toward integrated, clinician-centric approaches that elevate care quality differentiates winning investments.

For Investment Bankers: Strategic acquirers are expanding the buyer universe, with distributors and payers signaling increased interest in vertically enabled physician platforms to manage medical cost and performance.¹⁸ The Cencora acquisition of OneOncology from TPG for $3.6 billion exemplifies how large platforms with scaled networks, standardized operations and diversified revenue streams attract strategic acquirers willing to pay for reach and infrastructure. Advising on these strategic exits requires understanding both healthcare operations and corporate buyer motivations.

For Legal Advisors: Intensifying regulatory scrutiny demands more rigorous compliance documentation and measurable clinical outcomes. The patchwork of state laws — particularly around MSO structures, corporate practice of medicine and PE ownership — creates significant advisory opportunity. Healthcare transactions now require specialized due diligence addressing state-specific notification requirements, approval timelines, and potential transaction modifications. Legal advisors who can navigate this complexity while maintaining deal momentum command premium positions.

For Turnaround Advisors: The wave of healthcare Chapter 11 filings and liability management exercises creates sustained restructuring demand. Healthcare-specific restructuring requires understanding of Medicare and Medicaid certification requirements, state licensing implications and continuity of care obligations that complicate traditional distressed scenarios. The sector’s essential nature — patients require ongoing care regardless of corporate financial condition — creates both constraints and opportunities for advisors who understand the unique dynamics of healthcare workout situations.

Looking Forward: Convergence in 2026

If 2025 was defined by divergence — with top-tier assets attracting premium valuations while the lower middle market struggled — 2026 is increasingly shaping up as a year of convergence driven by healthcare’s recession-resistant fundamentals and renewed investor confidence.¹⁹ Several factors support a healthcare PE M&A rebound: greater clarity around earnings stabilization as payors appear to have repriced contracts; mounting exit pressure as sponsors hold assets beyond traditional horizons; and record dry powder coupled with easing interest rates.

Key trends likely to shape healthcare M&A opportunities include accelerating consolidation in post-acute care sectors such as ambulatory surgery centers, hospice and home health; sustained interest in AI-driven and tech-enabled platforms focused on interoperability, predictive analytics and value-based care models; and growing momentum in medtech solutions enhancing remote monitoring, care coordination and patient engagement.²⁰

For lenders, the healthcare sector’s complexity creates sustainable competitive advantage for those who invest in genuine expertise. According to Secured Research projections, healthcare-focused ABL capacity will need to expand by 35-40% through 2027 to support the sector’s financing requirements — creating opportunity for specialty lenders willing to build the infrastructure that healthcare middle market financing demands.

Sources:

1. Bain & Company, Healthcare Private Equity Market 2025: Resurgence and Record Growth, Global Healthcare PE Report 2026. https://www.bain.com/insights/healthcare-private-equity-market-2025-global-healthcare-private-equity-report-2026/
2. HealthLeaders Media, Healthcare Private Equity Deal Value Hits Record $191B in 2025. https://www.healthleadersmedia.com/ceo/healthcare-private-equity-deal-value-hits-record-191b-2025
3. ABF Journal, Healthcare ABL — An Ever-Changing Industry Landscape. https://www.abfjournal.com/articles/healthcare-abl-an-ever-changing-industry-landscape/
4. Bain & Company, Global Healthcare PE Report 2026.
5. Middle Market Growth, Trends Shaping Private Equity Investment in Healthcare, May 2025. https://middlemarketgrowth.org/bass-berry-sims-healthcare-m-a-outlook-trends/
6. Bain & Company, Why Mid-Market Healthcare Private Equity Firms Are Outperforming. https://www.bain.com/insights/why-mid-market-healthcare-private-equity-firms-are-outperforming-global-healthcare-private-equity-report-2025/
7. Middle Market Growth, Trends Shaping Healthcare M&A.
8. ProAssurance, Private Equity in Healthcare Today, December 2025. https://proassurance.com/knowledge-center/private-equity-in-healthcare-today
9. Bass Berry & Sims, Healthcare Private Equity: 2025 Outlook & Trends in M&A. https://www.bassberry.com/news/2025-healthcare-private-equity-outlook-trends/
10. SLR Healthcare ABL. https://slrhealthcareabl.com/
11. ABF Journal, Healthcare ABL — An Ever-Changing Industry Landscape.
12. Ibid.
13. CAIA, Asset-Based Lending: Coming of Age in the 2020s, June 2025. https://caia.org/blog/2025/06/30/asset-based-lending-coming-age-2020s
14. DLA Piper, Healthcare Private Equity M&A: Divergence in 2025, Convergence Ahead in 2026, January 2026. https://www.dlapiper.com/en-us/insights/publications/2026/01/healthcare-private-equity-m-a-divergence-in-2025-convergence-ahead-in-2026
15. Private Equity Stakeholder Project, PE Health Care Acquisitions October 2025, November 2025. https://pestakeholder.org/news/private-equity-health-care-acquisitions-october-2025/
16. DLA Piper, Healthcare Private Equity M&A 2026 Outlook.
17. Ibid.
18. Becker’s ASC, Private Equity’s Healthcare Strategy Has Shifted, December 2025. https://www.beckersasc.com/private-equity/private-equitys-healthcare-strategy-has-shifted-these-5-deals-explain-why/
19. DLA Piper, Healthcare Private Equity M&A 2026 Outlook.
20. Ibid.